Stockscreener 앱 받기
151.55
2.13%
3.16
시간 외 거래:
151.55
전일 마감가:
$148.39
열려 있는:
$149.29
하루 거래량:
218.42K
Relative Volume:
0.88
시가총액:
$4.36B
수익:
$241.52M
순이익/손실:
$52.37M
주가수익비율:
85.14
EPS:
1.78
순현금흐름:
$58.06M
1주 성능:
+6.25%
1개월 성능:
-8.06%
6개월 성능:
-25.59%
1년 성능:
+17.97%
1일 변동 폭
$146.01
$152.18
1주일 범위
$143.45
$152.18
52주 변동 폭
$107.50
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
KRYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
151.55 | 4.36B | 241.52M | 52.37M | 58.06M | 1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
High Growth Tech Stocks to Watch in January 2025 - Simply Wall St
(KRYS)Analyzing Krystal Biotech's Short Interest - Benzinga
Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Drops By 8.9% - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 8.9% in December - Defense World
GAMMA Investing LLC Lowers Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Jeune Aesthetics names new CFO ahead of Phase 2 trials - Investing.com
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - The Manila Times
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - GlobeNewswire Inc.
JPMorgan Chase & Co. Has $23.28 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
JPMorgan Chase & Co. Has $23.28 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
City Therapeutics Appoints Andy Orth as Chief Executive Officer - Marketscreener.com
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga
(KRYS) Proactive Strategies - Stock Traders Daily
Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $206.67 - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy (NASDAQ:KRYS) - Seeking Alpha
Principal Financial Group Inc. Sells 3,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Technical Pivots with Risk Controls - Stock Traders Daily
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth - Simply Wall St
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Avalon GloboCare (NASDAQ:ALBT) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Analysis - Defense World
Krystal Biotech (KRYS) – Research Analysts’ Weekly Ratings Changes - Defense World
Chardan Capital Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS) - Defense World
Krystal Biotech reports success with inhalable lung cancer drug in early-stage trial - Mugglehead
KRYS Reports Upbeat Initial Data From Lung Cancer Study Of KB707 - Barchart
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 - Yahoo Finance
Geode Capital Management LLC Purchases 11,411 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer - Marketscreener.com
Wellington Management Group LLP Buys 1,660 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech reports promising lung cancer trial results By Investing.com - Investing.com Australia
Krystal Biotech Reports Positive Results for KYANITE-1 Study - TipRanks
Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at Chardan Capital - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shares Gap UpWhat's Next? - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech reports promising lung cancer trial results - Investing.com
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Franklin Resources Inc. Has $43.77 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Teachers Retirement System of The State of Kentucky Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Lord Abbett & CO. LLC Sells 108,079 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech CEO Krishnan sells shares worth $4.12 million By Investing.com - Investing.com South Africa
Krystal Biotech's president Suma Krishnan sells $8.2 million in stock By Investing.com - Investing.com South Africa
Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech CEO Krishnan sells shares worth $4.12 million - Investing.com
Krystal Biotech's president Suma Krishnan sells $8.2 million in stock - Investing.com
KRYS Stock Down On Initial Clinical Updates On KB407 & KB408 - Barchart
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408 - MSN
Krystal Biotech announces initial update for KB408, KB407 - Yahoo Finance
Expert Ratings For Krystal Biotech - Benzinga
Krystal Biotech Reports Promising Results for Genetic Medicine - TipRanks
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels - The Manila Times
Krystal Biotech, Inc. Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 - Marketscreener.com
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):